Mylan Laboratories Ltd.

Medak, India

Mylan Laboratories Ltd.

Medak, India

Time filter

Source Type

Patent
Mylan Laboratories Ltd. | Date: 2014-11-28

The present disclosure relates to a solid dispersion of amorphous cobicistat and methods of its preparation. Cobicistat may be complexed with a pharmaceutically acceptable carrier such as -cyclodextrin or hydroxy! propyl -cyclodextrin. The present disclosure also provides pharmaceutical formulations for administration to patients and methods of their use.


Patent
Mylan Laboratories Ltd | Date: 2015-06-12

The present disclosure relates to crystalline forms of levomefolate calcium). The present disclosure also relates to a process for the preparation of crystalline forms of levomefolate calcium.


Patent
Mylan Laboratories Ltd. | Date: 2017-03-29

The present disclosure provides novel crystalline forms of cabozantinib (S)-malate, designated as form-M1, M2, M3 and M4 and novel crystalline forms of cabozantinib free base, form-M1, M2 and M3 and methods of their production. The present disclosure also provides processes for the preparation of crystalline cabozantinib (S)-malate form N-1. Formula (I)


The present disclosure relates to an improved process for the purification of fluticasone propionate by: a) dissolving fluticasone propionate in a ketone solvent to produce a mixture, b) heating the mixture slowly for 1-2 hours to get a clear solution, c) adding water to the step (b) solution at 50-60 C., d) cooling to 5 C. to 10 C., and e) isolating fluticasone propionate.


The present disclosure provides a process for the preparation a premix of raltegravir potassium form 3 with excipients. This premix may be used in the manufacture of pharmaceutical formulations containing raltegravir.


Patent
Mylan Laboratories Ltd. | Date: 2017-08-09

The present disclosure relates to solid dispersion of a complex of amorphous empagliflozin and a cyclodextrin.


The present invention provides an enzymatic process for the preparation of (S)-5-(4-Fluoro-phenyl)-5-hydroxy-Imorpholin-4-yl-pentan-1-one by the reduction of 1-(4-Fluoro-phenyl)-5-morpholin-4-yl-pentane-1,5-dione by using a suitable enzyme or by the resolution of (R, S)-5-(4-Fluoro-phenyl)-5-hydroxy-1 morpholin-4-yl-pentan-1-one by using an enzyme. The present invention also provides process for the preparation of Ezetimibe comprising the steps of a) protecting the componnd (S)-5-(4-Fluoro-phenyl)-5-hydroxy-1 morpholin-4-yl-pentan-1-one with hydroxy protecting group b) hydrolyzing the obtained componnd c) condensing with a chiral auxiliary d) reacting with an protected imine componnd e) converting to alkyl ester f) cyclizing and g) deprotecting to obtain Ezetimibe.


The present invention relates to novel and stable polymorphic forms of Perindopril (L)-Arginine designated as Form and amorphous form and processes for their preparation. The present invention also provides the novel polymorph Form with greater stability to heat and humidity and can be prepared on large scale by an efficient, economic and reproducible process.


Patent
Mylan Laboratories Ltd. | Date: 2015-02-04

The present disclosure relates to novel crystalline dolutegravir sodium Form-M2, Form-M3, Form-M4 and process for the preparation thereof.


Patent
Mylan Laboratories Inc. | Date: 2014-03-14

The presently disclosed subject matter is directed to a granule, wherein the granule has an active agent and a wax dispersed therein, and the granule exhibits excellent friability when compressed to form a pharmaceutical composition. The subject matter disclosed herein is also directed to methods of preparing the granules and the pharmaceutical compositions comprising the granules. The compositions and methods disclosed provide granules and pharmaceutical compositions for immediate release of the active agent and do not substantially prolong the release of the active agent from the granule.

Loading Mylan Laboratories Ltd. collaborators
Loading Mylan Laboratories Ltd. collaborators